title: Progress against follicular lymphoma.
abstract: OBJECTIVE
  To share the recent progress in research and new therapies against follicular lymphoma and highlight the exciting opportunities to improve the treatment of follicular lymphoma.
  
  
  RESULTS
  Follicular lymphoma has been somewhat neglected by the research community, but recent genomic studies have identified key genetic lesions in follicular lymphoma. In addition, a new murine model is available to explore the function of these lesions in the development, progression, and treatment of follicular lymphoma. Moreover, new small-molecule inhibitors are now available that target key pathways in follicular lymphoma including B-cell receptor signaling and histone modifiers.
  
  
  CONCLUSIONS
  Follicular lymphoma is a very common and still incurable form of lymphoma. However, recent genomic and in-vivo biological studies are beginning to unveil the molecular drivers of follicular lymphoma. This coincides with the development of effective small-molecule inhibitors against key targets. Together these developments suggest that we are at a long overdue watershed moment in the treatment of follicular lymphoma.
authors.affiliation: Department of Medicine, University of Arizona, Tucson, Arizona, USA.
authors.forename: Jonathan H
authors.initials: JH
authors.lastname: Schatz
authors.forename: Elisa
authors.initials: E
authors.lastname: Oricchio
authors.forename: Soham D
authors.initials: SD
authors.lastname: Puvvada
authors.forename: H Guido
authors.initials: HG
authors.lastname: Wendel
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D004195:Disease Models, Animal; D006801:Humans; D008224:Lymphoma, Follicular / Q000188:drug therapy*; D051379:Mice; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use*; D019253:Proto-Oncogene Proteins c-bcl-2 / Q000037:antagonists & inhibitors
chemical_list: D000970:Antineoplastic Agents; D047428:Protein Kinase Inhibitors; D019253:Proto-Oncogene Proteins c-bcl-2